Page 1, 2
1. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010 Mar 20;28(9):1467–1472.
2. Holmes MD, Olsson H, Pawitan Y, et al. Aspirin intake and breast cancer survival – a nation-wide study using prospectively recorded data in Sweden. BMC Cancer. 2014 Jun 2;14:391.
3. Bizzarri M, Carlomagno G. Inositol: history of an effective therapy for Polycystic Ovary Syndrome. Eur Rev Med Pharmacol Sci. 2014 Jul;18(13):1896–1903.
4. Kim JN, Han SN, Kim HK. Phytic acid and myo-inositol support adipocyte differentiation and improve insulin sensitivity in 3T3-L1 cells. Nutr Res. 2014 Aug;34(8):723–731. doi:10.1016/j.nutres.2014.07.015. Epub 2014 Jul 30.
5. Bizzarri and Carlomagno. 2014. Op cit.
6. Hanson AE. Hippocrates: Diseases of Women 1. Signs (Chic).1975;1:567–584.
7. Rosner F, Munter S. The Medical Aphorism of Moses Maimonides. Vol. 2. New York; Yeshiva University Press; 1971.
8. Azziz RA, Dumesic DA, Goodarzi MO. Polycystic ovary syndrome: an ancient disorder? Fertil Steril. 2011 Apr;95(5):1544–1548. doi:10.1016/j.fertnstert.2010.09.032. Epub 2010 Oct 27.
9. Polycystic ovary syndrome (PCOS): condition information [Web page]. National Institute of Health and Child Development. http://www.nichd.nih.gov/health/topics/PCOS/conditioninfo/Pages/default.aspx.
10. Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2003 Nov–Dec;7(6):151–159.
11. Papaleo E, Unfer V, Baillargeon JP, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007 Dec;23(12):700–703. Epub 2007 Oct 10.
12. Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007 Sep–Oct;11(5):347–354.
13. Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009 Mar–Apr;13(2):105–110.
14. Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol. 2010 Apr;26(4):275–280.
15. Le Donne M, Alibrandi A, Giarrusso R, Lo Monaco I, Muraca U. Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition. [In Italian.] Minerva Ginecol. 2012 Feb;64(1):23–29.
16. Colazingari S, Treglia M, Najjar R, Bevilacqua A. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013 Dec;288(6):1405–1411.
17. Pizzo A, Laganà AS, Barbaro L. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol. 2014 Mar;30(3):205–208.
18. Tais S. Myo-inositol in polycystic ovarian syndrome supplement acts as a natural insulin sensitizer in PCOS patients. Nat Med J. Aug 2013;5(6).
19. Genazzani AD, Santagni S, Ricchieri F, et al. Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome. J Obstet Gynaecol Res. 2014 May;40(5):1353–1360.
20. Faloia E, Canibus P, Gatti C, Frezza F, Santangelo M, Garrapa GG, Boscaro M. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. J Endocrinol Invest. 2004 May;27(5):424–429.
Megan Chmelik, a former dancer with Ballet Arizona, currently lives in Denver, Colorado, and works for Jacob Schor, ND. She will graduate in May 2015 from Metro State University with a major in integrative health care and then this summer move to Portland, Oregon, where she will start at National College of Natural Medicine, pursuing her doctorate in naturopathic medicine.
Dr. Schor graduated from NCNM in 1991 and has practiced in Denver, Colorado, ever since. He is a past president of the Colorado Association of Naturopathic Physicians. He has served on the Oncology Association of Naturopathic Physicians' board since 2008, as secretary, vice president, president and current "past president." He is an associate editor of the Natural Medicine Journal and a contributing writer to Naturopathy Digest, NDNR, the Townsend Letter, and other publications for the profession. He has served on the board of directors of the AANP and is a past chair of the AANP speaker selection committee. Dr. Schor, as a member of the AANP House of Delegates, was instrumental in passing the AANP's current Code of Ethics.
Page 1, 2